Novartis' commitment to innovation, ensuring that we develop and deliver effective new medicines quickly to the patients that need them, is underlined by our UK investment in R&D.
Novartis invests £1million per week on research and development with 16% of sales being reinvested back into R&D.
By 2016 Novartis will undertake more clinical trials in the UK than any other company.
R&D is a long and costly process. Most medicines take between 10-12 years from inception to being available for patients and only one in every 5 000 researched new compounds receives regulatory approval [ABPI].
Every day the pharmaceutical industry invests approximately £12.1 million in research and development in the UK [ABPI]. This investment is vital for the contribution it makes to enhancing our knowledge of diseases and how to treat them more effectively, and also for the benefit it provides to the wider UK economy in the UK, according to the Association of the British Pharmaceutical Industry (ABPI).
The UK has a strong reputation and heritage in medical research but faces increasing competition from other countries for investment in clinical trials.